Lova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.
Lova L. Sun, MD, MSCE
Advertisement
Articles by Lova L. Sun, MD, MSCE
Lova L. Sun, MD, MSCE discusses tisotumab vedotin (in patients with recurrent or metastatic (r/m) head and neck squamous cell carcinoma.
Lova L. Sun, MD, MSCE, discusses the association between duration of immunotherapy and overall survival in patients with advanced non–small-cell lung cancer.
Advertisement
Latest Updated Articles
Dr Sun on Tisotumab Vedotin in Recurrent or Metastatic HNSCCPublished: June 24th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
5